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Selenophosphate synthetase 2 is essential for selenoprotein biosynthesis
Xue-Ming XU*, Bradley A. CARLSON*, Robert IRONS*, Heiko MIX†, Nianxin ZHONG*, Vadim N. GLADYSHEV†
and Dolph L. HATFIELD*1
*Molecular Biology of Selenium Section, Laboratory of Cancer Prevention, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892,
U.S.A., and †Department of Biochemistry, University of Nebraska, Lincoln, NE 68588, U.S.A.
Selenophosphate synthetase (SelD) generates the selenium donor
for selenocysteine biosynthesis in eubacteria. One homologue
of SelD in eukaryotes is SPS1 (selenophosphate synthetase 1)
and a second one, SPS2, was identified as a selenoprotein in
mammals. Earlier in vitro studies showed SPS2, but not SPS1,
synthesized selenophosphate from selenide, whereas SPS1 may
utilize a different substrate. The roles of these enzymes in
selenoprotein synthesis in vivo remain unknown. To address their
function in vivo, we knocked down SPS2 in NIH3T3 cells using
small interfering RNA and found that selenoprotein biosynthesis
was severely impaired, whereas knockdown of SPS1 had no effect.
Transfection of SPS2 into SPS2 knockdown cells restored se-
lenoprotein biosynthesis, but SPS1 did not, indicating that SPS1
cannot complement SPS2 function. These in vivo studies indicate
that SPS2 is essential for generating the selenium donor for
selenocysteine biosynthesis in mammals, whereas SPS1 probably
has a more specialized, non-essential role in selenoprotein
metabolism.
Key words: RNA interference, selenocysteine, selenocysteine
synthesis, selenoprotein, selenoprotein synthesis, selenophos-
phate synthetase.
INTRODUCTION
Selenocysteine (Sec) is the 21st amino acid in the genetic code
[1,2] and, unlike other amino acids, the biosynthesis of seleno-
cysteine occurs on its tRNA [3,4]. Selenocysteine tRNA is initially
aminoacylated with serine by seryl-tRNA synthetase and is there-
fore designated selenocysteine tRNA[Ser]Sec. Although the bio-
synthetic pathway of selenocysteine was established in eubacteria
in the early 1990s [5], little was known about the biosynthesis of
this amino acid in eukaryotes and archaea until recently. The
biosynthetic pathway in eukaryotes and archaea was found to
have an extra step compared with eubacteria and proceeds from
seryl-tRNA[Ser]Sec to phosphoseryl-tRNA[Ser]Sec, which is catalysed
by phosphoseryl-tRNA[Ser]Sec kinase [6], and then to selenocysteyl-
tRNA[Ser]Sec, which is catalysed by selenocysteine synthase [7,8].
In eubacteria, the pathway proceeds from seryl-tRNA[Ser]Sec to se-
lenocysteyl-tRNA[Ser]Sec and a single selenocysteine synthase, de-
signated SelA (Escherichia coli selenocysteine synthase),
carries out this step [5]. The active donor of selenium that
makes selenocysteyl-tRNA[Ser]Sec from the intermediate generated
by SelA in bacteria is monoselenophosphate [9], which is
synthesized by selenophosphate synthetase from selenite and
ATP. Selenophosphate appears to be the universal donor in the
biosynthesis of this amino acid [8,9]. Selenophosphate synthetase
is designated SelD in bacteria and SPS2 (selenophosphate
synthetase 2) in mammals. Interestingly, in mammals, SPS2 is a
selenoprotein, which suggests that SPS2 can be an auto-regulator
as well as a regulator of selenoprotein synthesis as a whole [10,11].
In addition to SPS2, another protein, SPS1, was also originally
thought to have a role in selenophosphate synthesis [10–13].
Complementation studies with SPS1 and SPS2 in E. coli cells,
however, suggested that these proteins might have different roles.
Initially, the selenocysteine to cysteine mutant of SPS2 was found
to have low enzyme activity [10,11,14] and this mutant form
also complemented SelD in E. coli cells transfected with the
mammalian mutant protein [11,14]. SelD− E. coli cells could
also be complemented with SPS1 and SPS2, but the results
suggested that SPS2 was involved in the de novo synthesis of
selenophosphate, whereas SPS1 may have a role in recycling
selenocysteine by a selenium salvage system [15]. We recently
demonstrated that SPS2 synthesizes selenophosphate in vitro
and that this compound is the active donor for making se-
lenocysteine; we also showed that SPS1 does not synthesize
selenophosphate [8]. However, these studies were done in vitro
and, most importantly, the phenotypic analysis of mammalian
cells in which SPS1 and SPS2 have been targeted for removal,
and the complementation of such cells with SPS1 and SPS2, have
not been carried out. In the present study, we therefore examined
the effect of the knockdown of SPS1 and SPS2 in NIH3T3
cells on selenoprotein synthesis and have complemented SPS2
knockdown cells with SPS1 and SPS2. The results of the present
study demonstrate that the role of SPS2 is to provide the active
selenium donor for selenocysteine synthesis in mammals and that
SPS1 must have another role in selenium metabolism, which does
not involve monoselenophosphate synthesis.
EXPERIMENTAL
Materials
[75Se]Selenium (specific activity 1000 Ci/mmol) was purchased
from the Research Reactor Facility (University of Missouri,
Columbia, MO, U.S.A.), in the form of selenious acid and
Abbreviations used: DMEM, Dulbecco’s modified Eagle’s medium; FBS, fetal bovine serum; GAPDH, glyceraldehyde-3-phosphate dehydrogenase;
GPx1, glutathione peroxidase 1; HRP, horseradish peroxidase; mSPS, mouse selenophosphate synthetase; mSPS2-Cys, mSPS2 containing a
selenocysteine (UGA) to cysteine (UGC) mutation; RT, reverse transcription; SelA, Escherichia coli selenocysteine synthase; SelD, Escherichia coli
selenophosphate synthetase; SelT, selenoprotein T; siRNA, small interfering RNA; SPS, selenophosphate synthetase; TR1, thioredoxin reductase 1.
1 To whom correspondence should be addressed (email hatfield@mail.nih.gov).
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neutralized with NaOH before use. [α-32P]dCTP (specific activity
approx. 6000 Ci/mmol) and [α-32P]ATP (specific activity approx.
3000 Ci/mmol) were from NEN Corporation, and 3H-serine
(specific activity 29 Ci/mmol) and Hybond Nylon N+ membranes
were from Amersham Biosciences. NuPage 10% (w/v) polyacry-
lamide gels, PVDF membranes, Superscript II reverse transcrip-
tase, cell culture FBS (fetal bovine serum), DMEM (Dulbecco’s
modified Eagle’s medium), LipofectamineTM 2000, TRIzol®
reagent and Hygromycin B were purchased from Invitrogen. DNA
polymerase I large Klenow fragment was from New England
BioLabs, pET and pTriEx-4-Hygro vectors were from Novagen
and SuperSignal West Dura Extended Duration Substrate from
Pierce. Anti-His-tag antibodies were obtained from Qiagen, HRP
(horseradish peroxidase)-conjugated secondary antibodies from
Sigma and QuikChange® II Site-Directed Mutagenesis kits
from Stratagene. All other chemicals and reagents were obtained
commercially and were of the highest grade available.
Mammalian cell culture and transfection
Mouse embryonic fibroblast (NIH3T3) cells were obtained from
A.T.C.C. and cultured in DMEM supplemented with 10% (v/v)
FBS. Transfections were carried out using LipofectamineTM 2000
according to the manufacturer’s instructions. The medium of the
cells grown in the presence of selenium was supplemented with
200 nM sodium selenite or selenocysteine.
Generation of SPS siRNA (small interfering RNA) constructs
The Tet-on U6 vector used for expressing siRNA constructs
was prepared using the pU6-m4 Hygro vector [16] as the back-
bone. Two O2-type tet operators [17] were placed flanking
the TATA-box of the U6 promoter using QuikChange II site-
directed mutagenesis. This modified vector was designated as
pU6-TetO4m4.
For knocking down the expression of Sps1 (NM 175400)
and Sps2 (NM 009266), five separate 19 nt sequences (Sps1:
nucleotides 119–137, 418–436, 694–712, 1179–1197 and 1396–
1414; Sps2: nucleotides 567–585, 830–848, 1265–1283, 1684–
1702 and 1852–1870) were selected from each cDNA as being
unique to the respective gene using the online service, siDESIGN,
of Dharmacon Research. The corresponding siRNA constructs
within the pU6-TetO4m4 vector were prepared as described
previously [16]. The sequences of each SPS siRNA construct were
verified by sequencing, and the five constructs encoding the SPS
siRNA constructs and the pU6-TetO4m4 empty vector control
were transfected separately into NIH3T3 cells. After stabilizing
the transfected cells with 0.8 mg/ml of hygromycin, Sps1 and Sps2
mRNA levels were determined by Northern blot hybridization as
described below. On the basis of the knockdown of mRNA levels,
the best siRNA target sequence for each mRNA was identified
as 5′-GACGTAGAGTTGGCATACC-3′ (nucleotides 694–712)
in Sps1 and 5′-GGAACGAGAGAAGGTGACA-3′ (nucleotides
567–585) in Sps2 and these SPS siRNA constructs, designated
siSPS1 and siSPS2 respectively, were used in subsequent
experiments. The control vector, pU6-TetO4m4, was designated
pU6Tet control and it consisted of the same construct minus the
target sequence.
Northern blot analyses
Total RNA was isolated from various transfected cells using
TRIzol® reagent. Equal amounts of RNA (15 µg) from the dif-
ferent cells was loaded onto 1.2% (w/v) agarose gels with 4%
(v/v) formaldehyde and resolved by electrophoresis. The RNA
was then transblotted onto a nylon membrane, the membrane
hybridized with the appropriate [α-32P]dCTP-labelled probe and
analysed with a PhosphorImager for Northern blot analysis
as described previously [18]. The SPS1, SPS2 and GAPDH
(glyceraldehyde-3-phosphate dehydrogenase) probes were gene-
rated by either PCR or RT (reverse transcription)-PCR using
Superscript II reverse transcriptase and Universal Reference RNA
[18]. The sizes of all the probes generated by RT-PCR were
in the 500–1200 bp range. To detect an array of mRNAs on
the same membrane, the membranes, after an initial probing
for Sps1 mRNA, were stripped in boiling buffer [0.1 × SSC
(1×SSC is 0.15 M NaCl/0.015 M sodium citrate) and 0.1% SDS]
before being hybridized with a second probe, using successively
labelled SPS1, SPS2 or GAPDH cDNA probes. The hybridized
membranes were exposed to Phosphor screens and the screens
were then scanned using a Storm Image System (Molecular
Dynamics).
SPS gene cloning
Mouse Sps1 (NM 175400) and Sps2 (NM 009266), and E. coli
SelD (M30184) cDNA were amplified using RT-PCR as described
previously [8], and then cloned into the pTriEx-4 Hygro vector for
expression in mammalian cells. The SPS2-Cys [SPS2 containing
a selenocysteine (UGA) to cysteine (UGC) mutation] mutant was
generated as described previously [8]. Each gene contained a
His-tag on either the N- or C- terminus for easy detection by
Western blot analyses. To knock-in the selenocysteine (UGA) to
cysteine (UGC) mutant of mSPS2 (mouse SPS2), four degenerate
base mutations at nucleotides 570 (A → G), 573 (A → C), 576
(G → A) and 582 (G → C) in the 3′-position of each codon within
the siRNA target region that still encoded the same amino acids
of mSPS2 were carried out using QuikChange II site-directed
mutagenesis. The sequence was confirmed by DNA sequencing.
Selenoprotein labelling
To label the selenoprotein population in NIH3T3 cells, the
cells were grown overnight in DMEM with 10% (v/v) FBS
and 50 µCi/ml of [75Se]. After incubation, the labelled cells
were harvested, then washed in PBS, resuspended in 1 × SDS
loading buffer [4 ×:1 M Tris/HCl, pH 8.5, 8% (v/v) SDS, 40%
(v/v) glycerol, 1.6 mM EDTA, 0.075% Serva Blue G250 and
0.025% Phenol Red] and electrophoresed on NuPage 10% (w/v)
polyacrylamide gels (along with standard molecular mass markers
for assessing labelled selenoprotein sizes). After electrophoresis,
the gels were stained with Coomassie Blue, then dried before
being exposed to Phosphor screens, and the screens were scanned
using a Storm Image (PhosphorImager) system as described
previously [18].
Western blot analyses
For Western blot analyses, NIH3T3 cells were harvested,
resuspended in 1 × SDS loading buffer and the lysates were
ultrasonicated using a Sonic Dismembrator 550 (Fisher Scientific)
on power setting 5, with two 10 s pulses with a 2 min pause
inbetween to shear the genomic DNA. Aliquots (50 µg) of
proteins from cell lysates were electrophoresed on NuPage
10% (w/v) polyacrylamide gels and transferred to PVDF
membranes as described previously [18]. The membranes were
incubated with rabbit-anti-mouse GPx1 (glutathione peroxidase
1; diluted 1:1000), SelT (selenoprotein T; diluted 1:2000), TR1
c© The Authors Journal compilation c© 2007 Biochemical Society
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Figure 1 Knockdown of SPS1 and SPS2 in NIH3T3 cells
NIH3T3 cells were stably transfected with the siSPS1, siSPS2 and pU6Tet control constructs,
and the cells grown in the presence (lanes 2, 4 and 6) or absence (lanes 1, 3 and 5) of doxycycline
for 3 days. (A) Northern blot analysis of RNA was performed on extracts of siSPS1 (lanes 1
and 2) and siSPS2 (lanes 3 and 4) knockdown cells, and pU6Tet control cells (lanes 5 and 6).
The level of GAPDH mRNA was analysed as a loading control. (B) Upper panel, [75Se]-labelled
cell extracts were examined to evaluate selenoprotein synthesis in siSPS1 (lanes 1 and 2) and
siSPS2 (lanes 3 and 4) knockdown cells, and control cells (lanes 5 and 6). Molecular masses
are shown in kDa (KD). Coomassie Blue staining of the gel is shown as a protein loading control
in the lower panel.
(thioredoxin reductase 1; diluted 1:1000), β-tubulin (diluted
1:2000) or anti-His-tag (diluted 1:2000) antibodies, and HRP-
conjugated secondary antibodies (diluted 1:15000) were then
applied. The membranes were then washed with Tris-buffered sa-
line with Tween 20 (30 mM Tris/HCl, pH 7.4, 150 mM NaCl and
0.1% Tween 20), incubated in SuperSignal West Dura Extended
Duration Substrate and exposed to X-ray film as described pre-
viously [18].
RESULTS
siSPS1 and siSPS2 target their respective mRNAs
Northern blot analysis was used to document the effect of
siSPS1 and siSPS2 by reducing the steady-state levels of the
corresponding gene expression following transfection of NIH3T3
cells with the appropriate construct. Both SPS siRNAs knocked
down their corresponding mRNA in NIH3T3 cells effectively
when the constructs were induced with 5 µg/ml of doxycycline
for 3 days (Figure 1A, lanes 2 and 4). There did not appear to
be cross-knockdown of mRNA between the two SPS siRNAs.
Some leakiness apparently occurred in siSPS1 expression without
induction with doxycycline in the knockdown of SPS1, as the
amount of mRNA was less than that in the control (Figure 1A,
compare lane 1 with lanes 5 and 6).
Effect of siSPS1 and siSPS2 on selenoprotein expression
To examine the effect of the siSPS knockdown constructs on
selenoprotein expression, NIH3T3 cells stably transfected with
the siRNA or control constructs were grown in the presence or
absence of 5 µg/ml of doxycycline for 3 days and then labelled
with 50 µCi/ml of [75Se] for 16 h (Figure 1B). Clearly, inducing
siSPS2 had a pronounced effect on selenoprotein synthesis
(Figure 1B, lane 4), whereas inducing siSPS1 had no apparent
affect (Figure 1B, lane 2). Protein loading of each lane was
shown by Coomassie Blue staining (Figure 1B, lower panel).
We also labelled cells stably transfected with another siSPS2
construct that was found to be effective in knocking down SPS2
mRNA (target region, nucleotides 1684–1702). This construct
manifested the same effect on selenoprotein synthesis when grown
under identical conditions as the corresponding construct shown
in Figure 1 (results not shown), which provided strong evidence
that the phenotype resulting from the siSPS2 construct used
throughout this study is not the result of off-target effects.
We next examined whether selenoprotein synthesis could be
rescued in SPS2 knockdown cells by SPS1, SPS2 and/or SelD.
NIH3T3 cells that were stably transfected with the siSPS2
construct were grown in the presence or absence of doxycycline
for 3 days and then transfected with expression vectors encoding
mSPS1, mSPS2, mSPS2-Cys, SelD or the pTri-Ex4 control
vector. Several mutations were made within the siRNA target
site in the mSPS2 and mSPS2-Cys constructs, as described in the
Experimental section, to circumvent being targeted for removal
in the siSPS2 stably transfected cells. After 48 h of transfection
with the expression constructs, the cells were labelled with
50 µCi/ml of [75Se] for 16 h. mSPS2, mSPS2-Cys and SelD
restored selenoprotein synthesis, whereas mSPS1 did not
(Figure 2A). The protein loading of each lane was shown by Coo-
massie Blue staining (Figure 2A, lower panel). Western blot ana-
lysis using the anti-His-tag antibody showed that the expression
levels of the transfected mSPS1 and mSPS2-Cys were many
times higher than the expression of transfected mSPS2 and SelD
in siSPS2 stably transfected cells (Figure 2B, lanes 1 and 2).
However, mSPS2 and SelD were expressed in similar amounts in
cells transfected with the corresponding expression constructs
(Figure 2B, lanes 3 and 4). Even the elevated expression of
mSPS1 could not compensate for the loss of endogenous SPS2 in
mammalian cells.
Effect of selenium, siSPS1 and siSPS2 on selenoprotein expression
To assess the effect of the SPS siRNA constructs on selenoprotein
expression and, in addition, to examine the role that selenium
may have on selenoprotein expression in the knockdown cells,
NIH3T3 cells stably transfected with either the siSPS1, siSPS2
or control construct were grown in medium with or without
selenite or selenocysteine, and three individual selenoproteins
were examined by Western blot analysis (Figure 3). TR1, GPx1
and SelT were poorly expressed in SPS2 knockdown cells and
there did not appear to be any change in the expression of these
selenoproteins in cells grown in the presence or absence of selenite
or in selenocysteine-supplemented medium, with the possible
c© The Authors Journal compilation c© 2007 Biochemical Society
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Figure 2 Rescue of selenoprotein synthesis in SPS2 knockdown cells
NIH3T3 cells were stably transfected with the siSPS2 construct and grown in the presence
(lanes 1–5) or absence (lanes 6) of doxycycline for 3 days and then transiently transfected
with the mSPS1 (lanes 1), mSPS2-Cys (lanes 2), mSPS2 (lanes 3), SelD (lanes 4) or pU6Tet
control constructs (lanes 5 and 6). The cells, 48 h after transfection, were labelled overnight
with [75Se] and cell lysates electrophoresed on polyacrylamide gels for radiography or Western
blot analysis as described in the Experimental section. (A) Upper panel, [75Se] labelling of
transfected NIH3T3 cells is shown from each extract as indicated. Molecular masses are shown
in kDa (KD). Coomassie Blue staining of the gel is shown in the lower panel as a protein loading
control. (B) Western blot analysis of His-tagged proteins from each transfected NIH3T3 cell line
is shown as indicated. The amount of extract loaded onto gels in lanes 1–2 was 10-fold less
than in lanes 3–6.
exception of SelT, which manifested a slight induction in the
presence of either selenium source (Figure 3, lanes 4–6). TR1 was
expressed in SPS1 knockdown cells grown in medium without
a selenium source and the level of this protein was elevated
in the presence of selenite or selenocysteine (Figure 3, lanes
1–3). GPx1 and SelT were poorly expressed in the absence of
selenium and the levels of these selenoproteins were increased in
response to selenite or selenocysteine. The pattern of expression
of each selenoprotein was similar in the control cells to that
observed in the SPS1 knockdown cells, with the exception of
TR1, which appeared to be slightly higher in the presence and
absence of selenium or selenocysteine in the SPS1 knockdown
cells (Figure 3, compare lanes 7–9 with lanes 1–3).
Figure 3 Western blot analysis of siSPS1 and siSPS2 knockdown cells
NIH3T3 cells were stably transfected with the siSPS1 construct (lanes 1–3), the siSPS2 construct
(lanes 4–6) or the pU6Tet control construct (lanes 7–9), grown in the presence of doxycycline
for 3 days and then grown either in the absence (lanes 1, 4 and 7) or presence of 200 nM selenite
(lanes 2, 5 and 8) or 200 nM selenocysteine reduced from selenocystine (lanes 3, 6 and 9)
for an additional 2 days. The cell lysates of each transfected cell line were used for Western
blotting of TR1, GPx1 and SelT as described in the Experimental section. Western blot analysis
of β-tubulin was used as a loading control.
Effect of siSPS1 on selenoprotein turnover
To assess whether the knockdown of SPS1 may affect the turnover
of selenoproteins, NIH3T3 cells stably transfected with the siSPS1
construct or the control vector were grown in the presence
of 5 µg/ml of doxycycline for 3 days and then labelled with
50 µCi/ml of [75Se] for 16 h. The cells were washed to remove
the remaining [75Se] in the medium and then expanded in fresh
medium in 6-well plates with doxycycline, and the cells harvested
at 0, 8, 24, 32, 48, 56 and 72 h. The decline of [75Se] label in
selenoproteins over the 72 h period is shown in Figure 4. There
was no significant difference observed in the loss of [75Se] in
selenoproteins in the SPS1 knockdown cells and in the control
cells. This result indicates that the targeted removal of SPS1 did
not affect recycling of [75Se] in selenoprotein synthesis in NIH3T3
cells.
DISCUSSION
The characterization of the pair of SPSs in mammals remained
enigmatic in spite of numerous previous studies as discussed
in the Introduction. We have demonstrated recently that SPS2,
but not SPS1, can synthesize selenophosphate in vitro [8].
Furthermore, this earlier study used selenophosphate as the
substrate in the biosynthesis of selenocysteine to demonstrate
unequivocally that this compound is the active selenium donor
(see [8] and references therein). The emphasis of the present
study was to assess the consequences of removal of SPS1 and
SPS2 in a cell culture model. The reduction in the expression of
SPS2 inhibited selenoprotein expression, whereas the reduction
in SPS1 expression had no effect. In addition, SPS2, as well
as E. coli SelD, but not SPS1, complemented SPS2 knockdown
in cells by restoring selenoprotein synthesis. It would seem that
SPS2-generated selenophosphate must therefore be the sole donor
for selenocysteine synthesis from selenite in mammals, since
SPS2 and SelD synthesize selenophosphate and these proteins
complement SPS2-deficient cells.
Selenium is known to regulate selenoprotein expression
(reviewed in [1,2]) and some selenoproteins are more responsive
to changes in selenium status than others. For example, GPx1
is poorly expressed when selenium levels are low and elevates
dramatically when selenium levels are increased. In liver, levels
of GPx1 may change by over 100-fold in response to selenium
status. TR1 is also regulated by selenium, but its level changes
only slightly. These data are consistent with the idea that there is a
c© The Authors Journal compilation c© 2007 Biochemical Society
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Figure 4 Loss of [75Se]-labelling in selenoproteins in SPS1 knockdown
cells
NIH3T3 cells were stably transfected with the siSPS1 construct (lanes 2, 4, 6, 8, 10, 12 and 14)
or pU6Tet control construct (lanes 1, 3, 5, 7, 9, 11 and 13), grown in the presence of doxycycline
for 3 days and then labelled overnight with [75Se]. The cells were washed thoroughly to remove
[75Se], grown for 0 (lanes 1 and 2), 8 (lanes 3 and 4), 24 (lanes 5 and 6), 32 (lanes 7 and
8), 48 (lanes 9 and 10), 56 (lanes 11 and 12) and 72 h (lanes 13 and 14) and cell lysates
electrophoresed on polyacrylamide gels as described in the Experimental section. Molecular
masses are shown in kDa (KD) to the right-hand side of the upper panel. Coomassie Blue
staining of the gel is shown in the lower panel as a protein loading control.
hierarchy in selenoprotein expression with some selenoproteins,
such as GPx1, having low priority, and others, such as TR1,
having high priority for selenium supply [19,20]. In the present
study, supplementation of the media of control, SPS1 and
SPS2 knockdown cells with selenite or selenocysteine revealed
regulation of selenoprotein expression by both compounds. SPS1
knockdown cells manifested virtually the same response to
medium supplementation with selenium as control cells, with
the possible exception that TR1 may have been slightly over-
expressed compared with the control cells. Furthermore, SPS1
did not appear to have a role in the turnover of selenoproteins, as
the knockdown of this component did not affect selenoproteins
over a 72 h period following the labelling of the cells with
[75Se].
The role of SPS2 is clearly defined as the catalyst for generating
selenophosphate that is specifically used for selenoprotein syn-
thesis (see the present study, [8] and references therein). What
then is the role of SPS1? It belongs to the SPS protein family and
is highly homologous to SPS2 (see [8] and references therein),
but apparently has little or no affect on selenoprotein synthesis.
A previous report indicated that mammalian SPS1 might have
a role in recycling selenocysteine as tested in E. coli [15]. Our
results, as shown in Figures 3 and 4, however, suggested that
SPS1 is not involved in selenocysteine recycling in mammalian
cells. SPS1 forms a complex with several proteins involved in
the biosynthesis of selenocysteine [21], which suggests that it
has a role in some aspect of selenium metabolism. However,
this role is clearly different from that previously suspected for
this protein based on its homology to other members of the SPS
family, and future studies will be required to establish its function
in selenoprotein synthesis.
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